STOCK TITAN
  1. Home
  2. Sec-filings
  3. MLYS
  4. [Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported selling a total of 75,000 shares of common stock in open-market transactions on June 30, 2026. The filing shows two sales: 58,000 shares at a weighted-average price of $25.9432 per share and 17,000 shares at a weighted-average price of $26.8174 per share.

According to the footnotes, these transactions were executed under a Rule 10b5-1 trading plan adopted on December 30, 2025, and each reported price reflects multiple trades within disclosed price ranges. The Form 4 indicates that Congleton continues to hold a substantial direct stake in Mineralys common stock following these sales.

Positive

  • None.

Negative

  • None.

Insights

CEO executes pre-planned open-market sales totaling 75,000 shares.

Mineralys Therapeutics’ CEO, Jon Congleton, disclosed two open-market sales of common stock on June 30, 2026, totaling 75,000 shares. The weighted-average sale prices were $25.9432 and $26.8174, indicating execution across narrow intraday trading ranges.

A key detail is that footnotes state these sales were made under a Rule 10b5-1 trading plan adopted on December 30, 2025. Such plans are pre-arranged, which typically makes the timing more routine from an informational standpoint, even though they still reduce the CEO’s direct holdings.

The filing also shows that Congleton retains a significant direct position in Mineralys common stock after these transactions, suggesting the sales represent only a portion of his exposure. Subsequent company filings may provide additional context on any future 10b5-1 activity.

Insider Congleton Jon
Role Chief Executive Officer
Sold 75,000 shs ($1.96M)
Type Security Shares Price Value
Sale Common Stock 58,000 $25.9432 $1.50M
Sale Common Stock 17,000 $26.8174 $456K
Holdings After Transaction: Common Stock — 631,321 shares (Direct, null)
Footnotes (1)
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Total shares sold 75,000 shares Open-market sales on June 30, 2026 by CEO
Weighted-average sale price (58,000 shares) $25.9432 per share Common stock sale block on June 30, 2026
Weighted-average sale price (17,000 shares) $26.8174 per share Second common stock sale block on June 30, 2026
Lower price range block $25.5600–$26.5000 Price range for one sale block, per footnote
Higher price range block $26.6450–$26.8200 Price range for second sale block, per footnote
10b5-1 plan adoption date December 30, 2025 Plan governing June 30, 2026 sales
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Congleton Jon
(Last)(First)(Middle)
150 N. RADNOR CHESTER ROAD
SUITE F200
(Street)
RADNOR PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/30/2026S(1)58,000D$25.9432(2)631,321D
Common Stock06/30/2026S(1)17,000D$26.8174(3)614,321D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Remarks:
/s/ Adam Levy, Attorney-in-fact06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mineralys Therapeutics (MLYS) report for its CEO?

Mineralys Therapeutics reported that CEO Jon Congleton sold 75,000 shares of common stock in open-market transactions. The trades occurred on June 30, 2026, and were executed at weighted-average prices of $25.9432 and $26.8174 per share across multiple individual trades within stated price ranges.

At what prices did Mineralys CEO Jon Congleton sell MLYS shares?

Jon Congleton sold Mineralys Therapeutics common shares at weighted-average prices of $25.9432 and $26.8174. Footnotes explain these averages reflect multiple trades, with actual prices ranging from $25.5600 to $26.5000 in one block and $26.6450 to $26.8200 in the other.

How many Mineralys Therapeutics (MLYS) shares did the CEO sell in the latest Form 4?

The Form 4 shows CEO Jon Congleton sold a total of 75,000 Mineralys Therapeutics common shares. This consisted of 58,000 shares in one open-market transaction and 17,000 shares in a second, both reported for June 30, 2026, with separate weighted-average sale prices.

Were Jon Congleton’s MLYS stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the CEO’s June 30, 2026 Mineralys Therapeutics stock sales were executed under a Rule 10b5-1 trading plan. That plan was adopted on December 30, 2025, indicating the transactions were pre-arranged rather than opportunistic discretionary trades based on short-term developments.

Does the Mineralys CEO still own MLYS shares after these reported sales?

The Form 4 indicates Jon Congleton continues to hold a substantial direct position in Mineralys Therapeutics common stock after the June 30, 2026 sales. Exact remaining holdings are disclosed in the filing tables, showing that the transactions reduced, but did not eliminate, his equity stake.